联合治疗 UTHR 深 沪
已收盘 05-08 16:00:00 美东时间
564.94
-4.240
-0.74%
华盛通- 最 高573.52
- 今 开569.17
- 成交量 62.85万股
- 最 低 561.20
- 昨 收 569.18
- 总市值 239.74亿
- 52周最高 609.35
- 市盈率 静 20.27
- 换手率 1.48%
- 52周最低 272.12
- 委 比 -51.25%
- 总股本 4243.72万
- 历史最高 609.35
- 量 比 1.19
- 振 幅 2.16%
- 历史最低 36.55
- 每 手 1
- 风险率 96.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Transcript: United Therapeutics Q1 2026 Earnings Conference Call
United Therapeutics (NASDAQ:UTHR) reported first-quarter financial results on W...
05-07 00:29
财报速睇 | 联合治疗2026财年Q1营收7.82亿美元，同比下降1.6%；归母净利润2.75亿美元，同比下滑14.7%
华盛资讯5月6日讯，联合治疗公布2026财年Q1业绩，公司Q1营收7.82亿美元，同比下降1.6%，归母净利润2.75亿美元，同比下滑14.7%。
05-06 20:32
MannKind rises as collaboration with United Therapeutics expands
Shares of MannKind Corporation (MNKD) added ~16% in the premarket on Wednesday after the company announced plans for a new jointly developed therapy as part of an expanded license and collaboration ag...
05-06 19:37
财报速睇 | 联合治疗 2026财年Q1营收7.82亿美元，同比下降1.6%；归母净利润2.75亿美元，同比下滑14.7%
华盛资讯5月6日讯，联合治疗公布2026财年Q1业绩，公司Q1营收7.82亿美元，同比下降1.6%，归母净利润2.75亿美元，同比下滑14.7%。
05-06 19:22
United Therapeutics misses Q1 estimates
United Therapeutics press release (UTHR): Q1 GAAP EPS of $5.82 misses by $1.04. Revenue of $781.5M (-1.6% Y/Y) misses by $15.88M. More on United Therapeutics United Therapeutics: The Future Lies With ...
05-06 18:38
MannKind Develops Dry Powder Inhalation Formulation Of Ralinepag, Known As Ralinepag DPI, For United Therapeutics
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPIUnited
05-06 18:35
United Therapeutics Q1 EPS $5.82 Misses $6.92 Estimate, Sales $781.500M Miss $796.921M Estimate
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $5.82 per share which missed the analyst consensus estimate of $6.92 by 15.9 percent. This is a 12.22 percent decrease over earnings of $6.63 per share
05-06 18:30
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
MannKind and United Therapeutics are collaborating to develop a dry powder inhalation (DPI) formulation of ralinepag (MNKD-1501) for pulmonary arterial hypertension (PAH). United Therapeutics has made a $5 million payment to MannKind and plans to be the primary manufacturer. MannKind is eligible for up to $35 million in milestones and 10% royalties. Ralinepag DPI is expected to support once-daily dosing and is in early development stages. United ...
05-06 10:30
